| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg | |||
| 500mg | |||
| Other Sizes |
Purity: ≥98%
Temocapril (CS-622; CS622; temocaprilum; Aceco) is a potent and long-acting angiotensin-converting enzyme (ACE) inhibitor, approved for use (not in the USA) in the treatment of hypertension. Temocapril is a prodrug-type of ACE inhibitor not approved for use in the United States, but was approved in Japan and South Korea. Temocapril can also be used in hemodialysis patients without risk of serious accumulation.
| Targets |
Angiotensin-converting enzyme (ACE); [3]
|
|---|---|
| ln Vitro |
The prodrug of Temocaprilat, an ACE inhibitor, is Temocapril hydrochloride. Temoprilat hydrochloride is easily absorbed by the small intestine and then processed by CES1 (human carboxylesterase 1) in the liver to produce its active metabolite, temoprilat [1]. In spontaneously hypertensive rats (SHR), temocapril hydrochloride (500 nM) lessens the inhibitory effects of RS (N-acetyltetradecane renin substrate) and AngI (angiotensin) on neurogenic vasodilation [2]. The redox protein thioredoxin (TRX) is stimulated by temocapril hydrochloride (0.1–10 μM; 24 h), although the expression of the antioxidant enzymes Cu/ZnSOD and Mn-SOD is unaffected [3].
|
| ln Vivo |
In addition to improving autoimmune myocarditis, temocapril (10 mg/kg; oral; 21 days) increases the expression of thioredoxin in cardiomyocytes [3]. Temocapril (30 mg/kg; oral; once daily; for 4 weeks) did not lower renal Ang II levels but does suppress angiotensin I-induced hypertension, plasma, and renal ACE activity [4].
In a Lewis rat model of autoimmune myocarditis induced by porcine cardiac myosin, oral administration of Temocapril (10 mg/kg/day) from day 0 to day 21 post-immunization significantly ameliorated myocardial inflammation. This was evidenced by reduced myocardial mononuclear cell infiltration, decreased myocardial necrosis area, and lower myocardial inflammation scores compared to the control group. Additionally, Temocapril treatment significantly increased the expression level of thioredoxin (a redox-regulating protein) in cardiomyocytes, as detected by Western blot and immunohistochemical staining [3] |
| Cell Assay |
Western Blot analysis [3]
Cell Types: Cultured neonatal rat cardiomyocytes Tested Concentrations: 0.1 μM, 1 μM, 10 μM Incubation Duration: 24 hrs (hours) Experimental Results: The expression of redox protein thioredoxin (TRX) was enhanced by 1.9 times at 10 μM , and does not affect TRX2, Cu/Zn-SOD or Mn-SOD protein expression. |
| Animal Protocol |
Animal/Disease Models: Experimental autoimmune myocarditis (EAM) rat model [3]
Doses: 10 mg/kg Route of Administration: po (oral gavage); water management; 21-day Experimental Results: Improve EAM and prevent cellular protein oxidation. The expression of redox regulatory protein TRX in cardiomyocytes is enhanced. Animal/Disease Models: Male Sprague Dawley rat [4] Doses: 30 mg/kg Route of Administration: po (oral gavage), one time/day for 4 weeks. Experimental Results: Inhibited the increase in blood pressure caused by Ang I. For the autoimmune myocarditis model in Lewis rats: Rats were immunized with porcine cardiac myosin emulsified in complete Freund's adjuvant on day 0. Temocapril was dissolved in drinking water to achieve a dosage of 10 mg/kg/day, and administered orally to rats from day 0 to day 21 post-immunization. The control group received plain drinking water without Temocapril. On day 21, rats were euthanized, and hearts were harvested for histological analysis, Western blot, and immunohistochemical studies [3] |
| ADME/Pharmacokinetics |
Absorption, Distribution and Excretion
Temopril is rapidly absorbed in the gastrointestinal tract and converted into a diacid (active) metabolite, which inhibits angiotensin-converting enzyme (ACE) in plasma. Temopril is primarily excreted via the liver and kidneys. The urinary recovery rate is 19.4%. Biological Half-Life The biological half-life in patients with normal liver function is 13.1 hours. |
| Toxicity/Toxicokinetics |
Protein Binding
99.5%, including in individuals with impaired kidney function. |
| References |
|
| Additional Infomation |
Temocapril is a dipeptide. Temopril is a prodrug-type angiotensin I converting enzyme (ACE) inhibitor, not yet approved in the United States, but approved in Japan and South Korea. Temopril can also be used in hemodialysis patients without causing serious accumulation. Drug Indications Temopril is an ACE inhibitor primarily used to treat hypertension and congestive heart failure, diabetic nephropathy, and to improve the prognosis of coronary artery disease (including acute myocardial infarction). Pharmacodynamics Temopril is a prodrug of its active metabolite (diacid form), temoprilat, which contains a thiazole ring. Temoprilat isolated from rabbit lung has slightly higher ACE-inhibiting potency than enalaprilat. Angiotensin-converting enzyme inhibitors (ACEIs) exert their hemodynamic effects primarily by inhibiting the renin-angiotensin system. They can also modulate sympathetic nervous system activity and increase prostaglandin synthesis. They mainly cause vasodilation and mild natriuretic effects without affecting heart rate and myocardial contractility. Compared with other angiotensin-converting enzyme inhibitors, temopril has the advantage of rapid onset of action, and studies have shown that its binding affinity to vascular ACE is stronger than that of enalapril.
Temopril is an angiotensin-converting enzyme inhibitor (ACEI). Its ameliorative effect on autoimmune myocarditis is thought to be related to the enhanced expression of thioredoxin in cardiomyocytes, which may play an antioxidant and anti-inflammatory role in protecting myocardial tissue [3] |
| Molecular Formula |
C23H28N2O5S2
|
|
|---|---|---|
| Molecular Weight |
476.61
|
|
| Exact Mass |
476.144
|
|
| CAS # |
111902-57-9
|
|
| Related CAS # |
Temocapril hydrochloride;110221-44-8;Temocapril-d5;1356840-03-3
|
|
| PubChem CID |
443874
|
|
| Appearance |
Off-white to yellow solid powder
|
|
| Density |
1.33 g/cm3
|
|
| Boiling Point |
717.4ºC at 760 mmHg
|
|
| Melting Point |
>230ºC (dec)
|
|
| Flash Point |
387.7ºC
|
|
| LogP |
3.3
|
|
| Hydrogen Bond Donor Count |
2
|
|
| Hydrogen Bond Acceptor Count |
8
|
|
| Rotatable Bond Count |
11
|
|
| Heavy Atom Count |
32
|
|
| Complexity |
644
|
|
| Defined Atom Stereocenter Count |
3
|
|
| SMILES |
CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@H]2CS[C@@H](CN(C2=O)CC(=O)O)C3=CC=CS3
|
|
| InChi Key |
FIQOFIRCTOWDOW-BJLQDIEVSA-N
|
|
| InChi Code |
InChI=1S/C23H28N2O5S2/c1-2-30-23(29)17(11-10-16-7-4-3-5-8-16)24-18-15-32-20(19-9-6-12-31-19)13-25(22(18)28)14-21(26)27/h3-9,12,17-18,20,24H,2,10-11,13-15H2,1H3,(H,26,27)/t17-,18-,20-/m0/s1
|
|
| Chemical Name |
2-[(2S,6R)-6-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]-5-oxo-2-thiophen-2-yl-1,4-thiazepan-4-yl]acetic acid
|
|
| Synonyms |
|
|
| HS Tariff Code |
2934.99.9001
|
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
|
|||
|---|---|---|---|---|
| Solubility (In Vivo) |
|
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.0982 mL | 10.4908 mL | 20.9815 mL | |
| 5 mM | 0.4196 mL | 2.0982 mL | 4.1963 mL | |
| 10 mM | 0.2098 mL | 1.0491 mL | 2.0982 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA